Oncogene expressions detected by in situ hybridization of squamous metaplasia, dysplasia and primary lung cancer in human.

por Lee, J. D., Lee, D. H., Park, S. S., Shin, D. H., Chung, H. C., Lee, J. H.
Publicado 1989

A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

por Jeung, H-C, Rha, S Y, Shin, S J, Ahn, J B, Noh, S H, Roh, J K, Chung, H C
Publicado 2007

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

por Catenacci, D.V.T., Chung, H.C., Shen, L., Moehler, M., Yoon, H.H., Rosales, M.K., Kang, Y.-K.
Publicado 2021

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens

por Jeung, H-C, Rha, S Y, Cho, B C, Yoo, N C, Roh, J K, Roh, W J, Chung, H C, Ahn, J B
Publicado 2006

Point mutation at codon 12 of the c-Ha-ras gene in human gastric cancers.

por Koh, E. H., Chung, H. C., Lee, K. B., Han, E. K., Oh, S. H., Min, J. S., Choi, E. M., Youn, J. K., Kim, B. S.
Publicado 1992

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroeso...

por Boku, N, Ryu, M -H, Kato, K, Chung, H C, Minashi, K, Lee, K -W, Cho, H, Kang, W K, Komatsu, Y, Tsuda, M, Yamaguchi, K, Hara, H, Fumita, S, Azuma, M, Chen, L -T, Kang, Y -K
Publicado 2019

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: p...

por Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J
Publicado 2018

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

por Catenacci, D.V.T., Kang, Y.-K., Yoon, H.H., Shim, B.Y., Kim, S.T., Oh, D.-Y., Spira, A.I., Ulahannan, S.V., Avery, E.J., Boland, P.M., Chao, J., Chung, H.C., Gardner, F., Klempner, S.J., Lee, K.-W., Oh, S.C., Peguero, J., Sonbol, M.B., Shen, L., Moehler, M., Sun, J., Li, D., Rosales, M.K., Park, H.
Publicado 2022